An open-label, parallel-group study to determine the single and multiple dose pharmacokinetics of vildagliptin and its metabolites in mild, moderate or severe renal impaired patients compared to age, sex and weight-matched healthy volunteers following daily doses of 50 mg vildagliptin for 14 days

Trial Profile

An open-label, parallel-group study to determine the single and multiple dose pharmacokinetics of vildagliptin and its metabolites in mild, moderate or severe renal impaired patients compared to age, sex and weight-matched healthy volunteers following daily doses of 50 mg vildagliptin for 14 days

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2007

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 10 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top